Therapy of advanced breast cancer for patients with hormone receptor-positive / HER2-negative and HER2-positive tumors is changing real life. First results from the prospective, national research platform OPAL for patients with advanced breast cancer in Germany.

E. Stickeler, N. Harbeck, M. Thill, A. Nusch, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, M. Zahn, A. Welt, A. Wöckel, T. Decker, OPAL study group, 2019.

Cancer Res 80 (4 Suppl). https://doi.org/10.1158/1538-7445.SABCS19-P2-17-01